ProCE Banner Activity

ATLAS-PPX: Health-Related Quality of Life With Fitusiran Prophylaxis in Patients With Hemophilia A or B With or Without Inhibitors

Slideset Download
Conference Coverage

In this current analysis of the phase III ATLAS-PPX switch trial, monthly fitusiran prophylaxis improved HRQoL more than factor/BPA prophylaxis in adult and adolescent patients with hemophilia A or B with or without inhibitors.

Released: December 16, 2022

Expiration: December 15, 2023

No longer available for credit.
Begin Activity

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

AbbVie

Amgen

AstraZeneca

Epizyme

GSK

Incyte Corporation

Jazz Pharmaceuticals

Karyopharm Therapeutics Inc.

Novartis Pharmaceuticals Corporation

Sanofi

Seagen